“Advances in Drug Delivery Technologies for Oral Biologics”
- A notable and accelerating trend in the global oral proteins and peptides market is the rapid advancement in drug delivery technologies, particularly those enabling the protection and effective absorption of biologics in the gastrointestinal tract. These innovations are making oral delivery a viable alternative to traditional injections
- For instance, Oramed Pharmaceuticals is advancing its oral insulin candidate using a protective coating and enzyme inhibitors to prevent degradation in the stomach and enhance intestinal absorption. Similarly, Rani Therapeutics has developed a robotic pill that delivers biologics by injecting them directly into the intestinal wall after sensing optimal conditions
- These cutting-edge technologies enable therapeutic proteins and peptides to bypass enzymatic breakdown and low permeability challenges in the gut, improving bioavailability and therapeutic efficacy. Such innovations are opening doors to oral alternatives for chronic diseases that require frequent dosing, including diabetes and osteoporosis
- The growing number of collaborations between biotech firms and pharmaceutical companies to co-develop and commercialize oral biologics reflects rising industry confidence. For instance, Novo Nordisk’s oral semaglutide (Rybelsus) marked a breakthrough in GLP-1 therapies, offering a precedent for further development of peptide drugs in oral form
- These innovations are reshaping patient expectations, favoring user-friendly alternatives that improve adherence and quality of life. Consequently, companies are accelerating research into oral formulations of other peptides, such as parathyroid hormone, growth hormone, and calcitonin
- The demand for effective and patient-compliant oral peptide therapies is rapidly growing, fueled by a global shift towards less invasive treatments and enhanced chronic disease management across both developed and emerging markets
